Sanofi SA

Company Profile

• Business description

  Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from cardiometabolic will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs, with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

• Contact

  46, Avenue de la Great Army
  Paris75017
  FRA

  T: +33 153774000

  E: investor.relations@sanofi.com

  https://www.sanofi.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Drug Manufacturers - General

  Fiscal Year End

  31 December 2025

  Employees

  82,878